The need for adjuvants as a component of vaccines is still an important need despite of the stringent regulatory environment.
The global vaccine adjuvants market is expected to reach USD 769.4 Million by 2021 from USD 467.0 Million in 2016 at a CAGR of 10.5% from 2016 to 2021.
Patent: EP3007725 A1 (WO2014199297A1) publication: 20 April 2016. Priority: 10 June 2013. An international extension n. PCT/IB2014/062098, published on 18 December 2014 (WO2014/199297), was granted in EU (14741377.7), USA (14/896,789) and China (2014800330550). On 24 July 2019 (3007725), the patent was extended to the following European countries: UK, Austria, Belgium, Denmark, France, Finland, German, Greek, Italy, Ireland, Luxembourg, Norway, Holland, Portugal, Spain, Sweden, Suisse.
The present invention relates to beta-glycolipid derivatives, their preparation and use as adjuvants in vaccines, as being suitable for being co-administered with antigens for vaccine prophylaxis and therapy. In certain embodiments, the beta-glycolipid derivatives of the invention also in their salified or complex form, are suitable for being co-administered with antigens for both therapeutic and prophylactic purposes or for vaccine prophylaxis and therapy. Sulfavant’s activity has recently been demonstrated in vivo against melanoma cancer (see news section).